## Carl A K Borrebaeck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8359397/publications.pdf

Version: 2024-02-01

81900 98798 4,942 107 39 67 citations g-index h-index papers 111 111 111 5557 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. PharmacoEconomics - Open, 2021, 5, 77-88.	1.8	3
2	Identification of a serum biomarker signature associated with metastatic prostate cancer. Proteomics - Clinical Applications, 2021, 15, 2000025.	1.6	3
3	Animal-free alternatives and the antibody iceberg. Nature Biotechnology, 2020, 38, 1234-1239.	17.5	58
4	<p>Psychological Resilience and Health-Related Quality of Life in Swedish Women with Newly Diagnosed Breast Cancer</p> . Cancer Management and Research, 2020, Volume 12, 12041-12051.	1.9	14
5	Psychometric properties of the Connor-Davidson Resilience Scale (CD-RISC) in a non-clinical population in Sweden. Health and Quality of Life Outcomes, 2020, 18, 132.	2.4	44
6	Multiplex profiling of serum proteins in solution using barcoded antibody fragments and next generation sequencing. Communications Biology, 2020, 3, 339.	4.4	2
7	Skin Sensitization Testing—What's Next?. International Journal of Molecular Sciences, 2019, 20, 666.	4.1	9
8	Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. Journal of Clinical Oncology, 2018, 36, 2887-2894.	1.6	108
9	A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study. BMC Cancer, 2018, 18, 789.	2.6	11
10	Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nature Reviews Cancer, 2017, 17, 199-204.	28.4	318
11	Testing Human Skin and Respiratory Sensitizers—What Is Good Enough?. International Journal of Molecular Sciences, 2017, 18, 241.	4.1	3
12	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget, 2017, 8, 48507-48520.	1.8	63
13	Tumor tissue protein signatures reflect histological grade of breast cancer. PLoS ONE, 2017, 12, e0179775.	2.5	8
14	GARD: Genomic Allergen Rapid Detection., 2017,, 393-403.		1
15	Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays. Microarrays (Basel, Switzerland), 2016, 5, 16.	1.4	11
16	Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Engineering, Design and Selection, 2016, 29, 427-437.	2.1	35
17	Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis. Molecular Oncology, 2016, 10, 1305-1316.	4.6	25
18	Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach. New Biotechnology, 2016, 33, 503-513.	4.4	1

#	Article	IF	Citations
19	Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics. PLoS ONE, 2016, 11, e0159138.	2.5	27
20	Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In Vitro Assay Based on a Genomic Biomarker Signature. PLoS ONE, 2015, 10, e0118808.	2.5	34
21	A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. International Journal of Proteomics, 2015, 2015, 1-10.	2.0	26
22	Molecular design of recombinant scFv antibodies for site-specific photocoupling to $\hat{l}^2$ -cyclodextrin in solution and onto solid support. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 2164-2173.	2.3	8
23	Genomic Allergen Rapid Detection In-House Validation—A Proof of Concept. Toxicological Sciences, 2014, 139, 362-370.	3.1	27
24	Identification of plasma protein profiles associated with risk groups of prostate cancer patients. Proteomics - Clinical Applications, 2014, 8, 951-962.	1.6	10
25	Skin sensitizers differentially regulate signaling pathways in MUTZ-3 cells in relation to their individual potency. BMC Pharmacology & Expression (2014, 15, 5).	2.4	36
26	Multiplexing of miniaturized planar antibody arrays for serum protein profiling $\hat{a} \in \hat{a}$ a biomarker discovery in SLE nephritis. Lab on A Chip, 2014, 14, 1931-1942.	6.0	11
27	Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. Leukemia Research, 2014, 38, 682-690.	0.8	14
28	Miniaturization of multiplexed planar recombinant antibody arrays for serum protein profiling. Bioanalysis, 2014, 6, 1175-1185.	1.5	8
29	Recombinant Antibody Microarray for Profiling the Serum Proteome of SLE. Methods in Molecular Biology, 2014, 1134, 67-78.	0.9	8
30	Antibody Array Generation and Use. Methods in Molecular Biology, 2014, 1131, 563-571.	0.9	19
31	The GARD assay for assessment of chemical skin sensitizers. Toxicology in Vitro, 2013, 27, 1163-1169.	2.4	87
32	Protein Expression Profiling of Formalin-Fixed Paraffin-Embedded Tissue Using Recombinant Antibody Microarrays. Journal of Proteome Research, 2013, 12, 5943-5953.	3.7	16
33	Grading Breast Cancer Tissues Using Molecular Portraits. Molecular and Cellular Proteomics, 2013, 12, 3612-3623.	3.8	28
34	Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. International Journal of Cancer, 2013, 133, 2392-2397.	5.1	45
35	Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro. PLoS ONE, 2013, 8, e70596.	2.5	2
36	Identification of Serum Biomarker Signatures Associated with Pancreatic Cancer. Cancer Research, 2012, 72, 2481-2490.	0.9	98

#	Article	IF	CITATIONS
37	Quantitative Proteomics Targeting Classes of Motif-containing Peptides Using Immunoaffinity-based Mass Spectrometry. Molecular and Cellular Proteomics, 2012, 11, 342-354.	3.8	21
38	Serum proteome profiling of pancreatitis using recombinant antibody microarrays reveals diseaseâ€essociated biomarker signatures. Proteomics - Clinical Applications, 2012, 6, 486-496.	1.6	23
39	Epitopeâ€specificity of recombinant antibodies reveals promiscuous peptideâ€binding properties. Protein Science, 2012, 21, 1897-1910.	7.6	21
40	Viewpoints in clinical proteomics: When will proteomics deliver clinically useful information?. Proteomics - Clinical Applications, 2012, 6, 343-345.	1.6	9
41	Expanded clinical and experimental use of SOX11 - using a monoclonal antibody. BMC Cancer, 2012, 12, 269.	2.6	23
42	Design of recombinant antibody microarrays for urinary proteomics. Proteomics - Clinical Applications, 2012, 6, 291-296.	1.6	10
43	Knockâ€down of SOX11 induces autotaxinâ€dependent increase in proliferation <i>inÂvitro</i> and more aggressive tumors <i>inÂvivo</i> Molecular Oncology, 2011, 5, 527-537.	4.6	30
44	Histamine H4 receptor antagonism inhibits allergen-specific T-cell responses mediated by human dendritic cells. European Journal of Pharmacology, 2011, 651, 197-204.	3.5	20
45	Recombinant Antibodies for the Generation of Antibody Arrays. Methods in Molecular Biology, 2011, 785, 247-262.	0.9	32
46	A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics, 2011, 12, 399.	2.8	123
47	Design of recombinant antibody microarrays for membrane protein profiling of cell lysates and tissue extracts. Proteomics, 2011, 11, 1550-1554.	2.2	19
48	Surrogate antigens as targets for proteome-wide binder selection. New Biotechnology, 2011, 28, 302-311.	4.4	11
49	Proteomic Analysis and Discovery Using Affinity Proteomics and Mass Spectrometry. Molecular and Cellular Proteomics, 2011, 10, M110.003962.	3.8	16
50	Serum Protein Profiling of Systemic Lupus Erythematosus and Systemic Sclerosis Using Recombinant Antibody Microarrays. Molecular and Cellular Proteomics, 2011, 10, M110.005033.	3.8	63
51	Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14252-14257.	7.1	68
52	Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme. Journal of Neuro-Oncology, 2010, 97, 207-215.	2.9	9
53	Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics - Clinical Applications, 2010, 4, 591-602.	1.6	45
54	Tissue proteome profiling of preeclamptic placenta using recombinant antibody microarrays. Proteomics - Clinical Applications, 2010, 4, 794-807.	1.6	20

#	Article	IF	Citations
55	CD4+ T Cells Have a Key Instructive Role in Educating Dendritic Cells in Allergy. International Archives of Allergy and Immunology, 2009, 149, 1-15.	2.1	7
56	Strategy for surveying the proteome using affinity proteomics and mass spectrometry. Proteomics, 2009, 9, 1511-1517.	2.2	81
57	Attovialâ€based antibody nanoarrays. Proteomics, 2009, 9, 5406-5413.	2.2	11
58	Design of high-density antibody microarrays for disease proteomics: Key technological issues. Journal of Proteomics, 2009, 72, 928-935.	2.4	135
59	Antibody-Based Microarrays. Methods in Molecular Biology, 2009, 509, 57-84.	0.9	65
60	Selection and Characterization of Antibodies from Phage Display Libraries Against Internalizing Membrane Antigens. Methods in Molecular Biology, 2009, 480, 113-127.	0.9	5
61	Transferring proteomic discoveries into clinical practice. Expert Review of Proteomics, 2009, 6, 11-13.	3.0	28
62	Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica, 2009, 94, 1563-1568.	3.5	131
63	Detection of pancreatic cancer using antibody microarrayâ€based serum protein profiling. Proteomics, 2008, 8, 2211-2219.	2.2	108
64	Multiplexed Lipid Dipâ€Pen Nanolithography on Subcellular Scales for the Templating of Functional Proteins and Cell Culture. Small, 2008, 4, 1785-1793.	10.0	142
65	Augmented Phl p 5-specific Th2 response after exposure of dendritic cells to allergen in complex with specific IgE compared to IgG1 and IgG4. Clinical Immunology, 2008, 128, 358-365.	3.2	27
66	B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Letters, 2008, 259, 138-145.	7.2	22
67	Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. European Journal of Cancer, 2008, 44, 472-480.	2.8	106
68	Design of Recombinant Antibody Microarrays for Cell Surface Membrane Proteomics. Journal of Proteome Research, 2008, 7, 319-327.	3.7	33
69	Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood, 2008, 111, 1617-1624.	1.4	40
70	Nuclear expression of the non–B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 2008, 111, 800-805.	1.4	185
71	High-throughput proteomics using antibody microarrays: an update. Expert Review of Molecular Diagnostics, 2007, 7, 673-686.	3.1	113
72	Design of Recombinant Antibody Microarrays for Serum Protein Profiling:  Targeting of Complement Proteins. Journal of Proteome Research, 2007, 6, 3527-3536.	3.7	81

#	Article	IF	CITATIONS
73	Quantitative interpretation of gold nanoparticle-based bioassays designed for detection of immunocomplex formation. Biointerphases, 2007, 2, 6-15.	1.6	19
74	Design of atto-vial based recombinant antibody arrays combined with a planar wave-guide detection system. Proteomics, 2007, 7, 540-547.	2.2	29
75	Design of recombinant antibody microarrays for complex proteome analysis: Choice of sample labelingâ€tag and solid support. Proteomics, 2007, 7, 3055-3065.	2.2	102
76	ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nature Methods, 2007, 4, 13-17.	19.0	231
77	Progress in miniaturization of protein arraysâ€"a step closer to high-density nanoarrays. Drug Discovery Today, 2007, 12, 813-819.	6.4	109
78	Antibody-Based Microarrays., 2007,, 175-189.		0
79	Antibody Microarrays: Current Status and Key Technological Advances. OMICS A Journal of Integrative Biology, 2006, 10, 411-427.	2.0	100
80	The Human IgE-encoding Transcriptome to Assess Antibody Repertoires and Repertoire Evolution. Journal of Molecular Biology, 2006, 362, 212-227.	4.2	39
81	One-Step Fractionation of Complex Proteomes Enables Detection of Low Abundant Analytes Using Antibody-Based Microarrays. Journal of Proteome Research, 2006, 5, 170-176.	3.7	40
82	Improved affinity coupling for antibody microarrays: Engineering of double-(His)6-tagged single framework recombinant antibody fragments. Proteomics, 2006, 6, 4227-4234.	2.2	59
83	Functional and transcriptional profiling of MUTZ-3, a myeloid cell line acting as a model for dendritic cells. Immunology, 2006, 117, 156-166.	4.4	76
84	Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. International Journal of Cancer, 2006, 118, 2092-2097.	5.1	35
85	Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies. International Journal of Cancer, 2006, 119, 349-358.	5.1	23
86	The nuclear DNA repair protein Ku70/80 is a tumor-associated antigen displaying rapid receptor mediated endocytosis. International Journal of Cancer, 2006, 119, 2492-2496.	5.1	12
87	From Gene Expression Analysis to Tissue Microarrays. Molecular and Cellular Proteomics, 2006, 5, 1072-1081.	3.8	34
88	Identification of Protein Expression Signatures Associated with Helicobacter pylori Infection and Gastric Adenocarcinoma Using Recombinant Antibody Microarrays. Molecular and Cellular Proteomics, 2006, 5, 1638-1646.	3.8	92
89	Antibody microarray-based oncoproteomics. Expert Opinion on Biological Therapy, 2006, 6, 833-838.	3.1	53
90	Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma. Leukemia Research, 2005, 29, 205-213.	0.8	17

#	Article	IF	CITATIONS
91	Biocompatibility of surfaces for antibody microarrays: design of macroporous silicon substrates. Analytical Biochemistry, 2005, 341, 204-213.	2.4	73
92	Gravimetric antigen detection utilizing antibody-modified lipid bilayers. Analytical Biochemistry, 2005, 345, 72-80.	2.4	37
93	Microarrays based on affinity-tagged single-chain Fv antibodies: Sensitive detection of analyte in complex proteomes. Proteomics, 2005, 5, 1281-1291.	2.2	90
94	Genomic and functional delineation of dendritic cells and memory T cells derived from grass pollen-allergic patients and healthy individuals. International Immunology, 2005, 17, 401-409.	4.0	21
95	A novel mammalian display system for the selection of protein–protein interactions by decoy receptor engagement. Journal of Molecular Recognition, 2004, 17, 316-322.	2.1	5
96	Profiling of internalizing tumor-associated antigens on breast and pancreatic cancer cells by reversed genomics. Cancer Letters, 2004, 208, 235-242.	7.2	10
97	High-throughput proteomics using antibody microarrays. Expert Review of Proteomics, 2004, 1, 355-364.	3.0	63
98	Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. Haematologica, 2004, 89, 686-95.	3.5	21
99	Patterns of DNA-Labeled and scFv-Antibody-Carrying Lipid Vesicles Directed by Material-Specific Immobilization of DNA and Supported Lipid Bilayer Formation on an Au/SiO2 Template. ChemBioChem, 2003, 4, 339-343.	2.6	132
100	Pre-assembly of the extracellular domains of CD40 is not necessary for rescue of mouse B cells from anti-immunoglobulin M-induced apoptosis. Immunology, 2003, 108, 452-457.	4.4	8
101	Recombinant antibody microarrays—a viable option?. Nature Biotechnology, 2003, 21, 223-223.	17.5	47
102	Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. International Immunology, 2002, 14, 1203-1213.	4.0	51
103	Antibody Evolution from the Centre to the Periphery: Applied to a Human Antibody Fragment Recognising the Tumour-associated Antigen Mucin-1. Journal of Molecular Biology, 2002, 318, 407-416.	4.2	11
104	Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology, 2002, 106, 456-463.	4.4	17
105	Antibody evolution beyond Nature. Nature Biotechnology, 2002, 20, 1189-1190.	17.5	38
106	Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Research, 2002, 62, 4398-405.	0.9	92
107	A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells. Cancer Immunology, Immunotherapy, 1999, 47, 249-256.	4.2	7